Duke Center for Neurodegeneration and Neurotherapeutics, Duke University, Durham, North Carolina, USA.
Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
Mov Disord. 2022 Jul;37(7):1454-1464. doi: 10.1002/mds.29043. Epub 2022 May 6.
Pathogenic leucine-rich repeat kinase 2 LRRK2 mutations may increase LRRK2 kinase activity and Rab substrate phosphorylation. Genetic association studies link variation in LRRK2 to idiopathic Parkinson disease (iPD) risk.
Through measurements of the LRRK2 kinase substrate pT73-Rab10 in urinary extracellular vesicles, this study seeks to understand how LRRK2 kinase activity might change with iPD progression.
Using an immunoblotting approach validated in LRRK2 transgenic mice, the ratio of pT73-Rab10 to total Rab10 protein was measured in extracellular vesicles from a cross-section of G2019S LRRK2 mutation carriers (N = 45 participants) as well as 485 urine samples from a novel longitudinal cohort of iPD and controls (N = 85 participants). Generalized estimating equations were used to conduct analyses with commonly used clinical scales.
Although the G2019S LRRK2 mutation did not increase pT73-Rab10 levels, the ratio of pT73-Rab10 to total Rab10 nominally increased over baseline in iPD urine vesicle samples with time, but did not increase in age-matched controls (1.34-fold vs. 1.05-fold, 95% confidence interval [CI], 0.004-0.56; P = 0.046; Welch's t test). Effect estimates adjusting for sex, age, disease duration, diagnosis, and baseline clinical scores identified increasing total Movement Disorder Society-Sponsored Revision of the Unified (MDS-UPDRS) scores (β = 0.77; CI, 0.52-1.01; P = 0.0001) with each fold increase of pT73-Rab10 to total Rab10. Lower Montreal Cognitive Assessment (MoCA) score in iPD is also associated with increased pT73-Rab10.
These results provide initial insights into peripheral LRRK2-dependent Rab phosphorylation, measured in biobanked urine, where higher levels of pT73-Rab10 are associated with worse disease progression. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.
致病性富含亮氨酸重复激酶 2(LRRK2)突变可能会增加 LRRK2 激酶的活性并促进 Rab 底物磷酸化。遗传关联研究将 LRRK2 中的变异与特发性帕金森病(iPD)风险联系起来。
通过测量尿细胞外囊泡中 LRRK2 激酶底物 pT73-Rab10,本研究旨在了解 LRRK2 激酶活性如何随 iPD 进展而变化。
本研究使用在 LRRK2 转基因小鼠中验证的免疫印迹方法,测量了 G2019S LRRK2 突变携带者(N=45 名参与者)的细胞外囊泡中 pT73-Rab10 与总 Rab10 蛋白的比值,以及一项新的 iPD 和对照组的纵向队列的 485 个尿液样本(N=85 名参与者)。使用广义估计方程进行分析,并使用常用的临床量表。
尽管 G2019S LRRK2 突变并未增加 pT73-Rab10 水平,但随着时间的推移,iPD 尿液囊泡样本中的 pT73-Rab10 与总 Rab10 的比值名义上有所增加,但在年龄匹配的对照组中并未增加(1.34 倍比 1.05 倍,95%置信区间 [CI],0.004-0.56;P=0.046;Welch's t 检验)。调整性别、年龄、疾病持续时间、诊断和基线临床评分的效应估计值表明,随着 pT73-Rab10 与总 Rab10 的比值每增加一倍,运动障碍协会赞助的修订版统一(MDS-UPDRS)评分(β=0.77;CI,0.52-1.01;P=0.0001)也会增加。iPD 患者的蒙特利尔认知评估(MoCA)评分较低也与 pT73-Rab10 增加有关。
这些结果首次提供了有关外周 LRRK2 依赖性 Rab 磷酸化的见解,这些磷酸化是在生物样本库的尿液中测量的,其中 pT73-Rab10 水平较高与疾病进展恶化有关。